Diagnostic and Prognostic Value of Stress CMR Imaging in Patients with Known or Suspected Coronary Artery Disease: a Twenty-Year Meta-Analysis

Running title: Stress CMR in Stable Chest Pain

5

4

6 Fabrizio Ricci MD, PhD, MSc^{a,b,c}, Mohammed Y Khanji MBBCh, PhD^{c,d,e}, Giandomenico

7 Bisaccia MD^a, Alberto Cipriani, MD^f, Annamaria Di Cesare, MD^g, Laura Ceriello, MD^a,

8 Cesare Mantini, MD, PhD^a, Marco Zimarino, MD, PhD^a, Artur Fedorowski, MD, PhD^{b,h},

9 Sabina Gallina MD, PhD^a, Steffen E Petersen MD, DPhil, MSc, MPH^{d,e, i,j}, Chiara Bucciarelli-

10 Ducci MD, PhD^{k,l^*}

11 ^a Department of Neuroscience, Imaging and Clinical Sciences, "G. d'Annunzio" University of Chieti-

12 Pescara, 66100 Chieti, Italy; <u>giandomenico.bisaccia@unich.it;</u> sabina.gallina@unich.it;

13 <u>lauraceriello@libero.it; cesare.mantini@gmail.com; m.zimarino@unich.it; fabrizio.ricci@unich.it</u>

14 ^b Department of Clinical Sciences, Lund University, 214 28 Malmö, Sweden

^c William Harvey Research Institute, NIHR Barts Biomedical Research Centre, Queen Mary University

16 London, Charterhouse Square, London, EC1M 6BQ, UK; <u>m.khanji@qmul.ac.uk; s.e.petersen@qmul.ac.uk</u>

- ^d Newham University Hospital, Glen Road, Plaistow, Barts Health NHS Trust. London E13 8SL, UK
- ^e Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, West Smithfield, EC1A 7BE,
 London, UK;

^f Department of Cardiac, Thoracic and Vascular Sciences and Public Health, University of Padova, Italy;
 <u>alberto.cipriani@unipd.it</u>

^g U.O. Cardiologia, Ospedale di Rimini, AUSL della Romagna, Italy; <u>annamaria.dicesare@auslromagna.it</u>
 ^g Department of Clinical Sciences, Lund University, 214 28 Malmö, Sweden

^h Department of Cardiology, Karolinska University Hospital, and Department of Medicine, Karolinska
 Institute, Stockholm, Sweden; <u>artur.fedorowski@ki.se</u>

26 ⁱ The Alan Turing Institute, London, UK

27 ^j Health Data Research UK, London, UK

^k Royal Brompton and Harefield Hospitals, Guys and St Thomas NHS Trust London, United Kingdom of
 Great Britain & Northern Ireland; <u>c.bucciarelli-ducci@rbht.nhs.uk</u>

¹ School of Biomedical Engineering and Imaging Sciences, Faculty of Life Sciences and Medicine, Kings
 College London, United Kingdom

* Corresponding author - Royal Brompton Hospital, Sydney Street, London, SW3 6NP, United Kingdom
 E-mail address: <u>c.bucciarelli-ducci@rbht.nhs.uk</u>

- **34** Word count: Text only: 3292 words (not including title page, key points, abstract,
- 35 references, acknowledgments, and legends)
- **36 Date of revision:** 10/04/2023

37	KEY POINTS
38	QUESTION
39	What is the diagnostic and prognostic value of stress CMR imaging for the evaluation of
40	stable chest pain?
41	
42	FINDINGS
43	In the largest contemporary meta-analysis pooling more than 65,000 patients and 381,357
44	person-years of follow-up, stress CMR yields high diagnostic accuracy and effective risk
45	stratification in patients with known or suspected CAD, particularly with 3-Tesla imaging.
46	
47	MEANING
48	Combined assessment of inducible myocardial ischemia and LGE by stress CMR imaging is
49	a highly effective pathway to diagnose and risk stratify patients with stable chest pain.

50 Normal stress CMR is associated with low risk of cardiovascular events for at least 3.5 years.

51	Abstract
52	Importance: Clinical utility of stress cardiovascular magnetic resonance (CMR) in stable chest
53	pain is still debated and low-risk period for adverse events following a negative test is
54	unknown.
55	Objective: To provide contemporary quantitative data synthesis of diagnostic accuracy and
56	prognostic value of stress CMR in stable chest pain.
57	Data Sources: We searched PubMed, Embase, Cochrane and PROSPERO databases, and
58	Clinical Trials Registry for potentially relevant articles.
59	Study Selection: CMR studies reporting estimates of diagnostic accuracy and/or raw data of
60	adverse cardiovascular events for participants with either positive or negative stress CMR.
61	Data Extraction and Synthesis: This meta-analysis was planned, conducted, and reported in
62	agreement with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses.
63	Two reviewers extracted data and assessed the risk of bias.
64	Main Outcomes and Measures: Diagnostic odds ratio (DOR), sensitivity, specificity, area
65	under the curve (AUC), odds ratios (ORs) and annualized event rates (AERs) for all-cause
66	death, cardiovascular death, and major adverse cardiac events (MACE) defined as the
67	composite of myocardial infarction and cardiovascular death.
68	Results: We identified 33 diagnostic studies pooling 7,815 individuals and 31 prognostic
69	studies pooling 67,080 patients (mean follow-up: 3.5 years/381,357 person-years). Stress
70	CMR yielded a DOR of 26.4 (95%CI:10.6-65.9), a sensitivity of 81% (95%CI:68-89%), a
71	specificity of 86% (95%CI:75-93%), and an AUC of 0.84 (95%CI:0.77-0.89) for the
72	detection of functionally obstructive CAD. In subgroup analysis, stress CMR yielded higher
73	diagnostic accuracy in the setting of suspected CAD (DOR=53.4) or when using 3-Tesla

74 imaging (DOR=33.2). Presence of stress-inducible ischemia was associated with higher all-

- 75 cause mortality (OR:2.0;95%CI:1.7-2.3), cardiovascular mortality (OR:6.4;95%CI:4.5-9.1),
- 76 and increased risk of MACE (OR:5.3;95%CI:4.0-7.0). Presence of late gadolinium
- enhancement (LGE) was associated with higher all-cause mortality (OR 2.22; 95%CI:1.99-
- 78 2.47), cardiovascular mortality (OR 6.03; 95%CI:2.76-13.13), and increased risk of MACE
- 79 (5.42; 95%CI:3.42-8.6). After a negative test, pooled AERs for cardiovascular mortality and

80 MACE remained <1%.

- 81 Conclusion and Relevance: Stress CMR yields high diagnostic accuracy and delivers robust
- 82 prognostication, particularly with 3-Tesla scanners. While both inducible myocardial
- 83 ischemia and LGE portend excess mortality and increased risk of MACE, normal stress CMR
- 84 is associated with low risk of cardiovascular events for at least 3.5 years.
- 85 Keywords: stress CMR, ischemia, diagnostic accuracy, prognosis, chest pain, meta-analysis.

86 87	Non-standard Abbreviations and Acronyms									
88	AER	Annualized event rate								
89	AUC	Area under the receiver operating characteristic curve								
90	CMR	Cardiovascular magnetic resonance								
91	DAN-NICAD	Danish Study of Non-Invasive Diagnostic Testing in Coronary Artery Disease								
92	DOR	Diagnostic odds ratio								
93	FFR	Fractional flow reserve								
94	ICA	Invasive coronary angiography								
95	LGE	Late gadolinium enhancement								
96	MACE	Major adverse cardiovascular events								
97 98	MR-IMPACT II	The Magnetic Resonance Imaging for Myocardial Perfusion Assessment in Coronary artery disease								
99 100	MR-INFORM	The Myocardial Perfusion CMR versus Angiography and FFR to Guide the Management of Patients with Stable Coronary Artery Disease								
101	nLR	Negative likelihood ratio								
102	pLR	Positive likelihood ratio								
103	SPINS	Stress CMR Perfusion Imaging in the United States)								

104 Introduction

105 Coronary artery disease (CAD) is the leading cause of cardiovascular morbidity and mortality 106 worldwide. Non-invasive imaging plays a central role in the recent 2019 European Society of 107 Cardiology guidelines on chronic coronary syndromes and in the 2021 AHA/ACC guidelines 108 on chest pain. Evaluation of inducible myocardial ischemia by assessment of perfusion 109 reserve or regional wall motion abnormalities is a key element in the diagnostic work-up of 110 patients with stable chest pain and an intermediate-to-high pre-test probability of CAD^{1,2}.

111 New recommendations for the use of non-invasive imaging in coronary syndromes developed 112 by a transatlantic intersociety task force endorse the use of stress cardiovascular magnetic 113 resonance (CMR) to detect ischemia and guide clinical decision-making in patients with high 114 intermediate pre-test clinical likelihood of CAD³. Consistently, the 2021 American College 115 of Cardiology and American Heart Association guidelines for the evaluation and diagnosis of 116 chest pain delivered Class I and IIa recommendations for stress CMR as a first-line functional 117 investigation for evaluation of chest pain in intermediate-risk patients with known or 118 suspected CAD⁴.

CAD is one of the primary indications for CMR^{5,6} and utilization of stress CMR has been 119 120 steadily growing worldwide⁶. However, contemporary data on the diagnostic accuracy and 121 prognostic value of stress CMR in patients with known or suspected CAD is currently 122 lacking. After twenty years of clinical use and the recent completion of large multicenter 123 observational studies^{7,8} and randomized clinical trials^{9,10}, which were not included in previous systematic reviews and meta-analyses¹¹⁻¹⁴, we have appraised the best available 124 125 contemporary evidence to deliver the most updated quantitative synthesis on diagnostic 126 accuracy and prognostic value of stress CMR for the assessment of chest pain.

127 Methods

132

128 This systematic review and meta-analysis was planned, conducted, and reported according to

129 the PRISMA statement for design, analysis, and reporting of meta-analyses of randomized

130 and observational studies¹⁵ and the Cochrane Handbook for Systematic Reviews of

131 Diagnostic Test Accuracy¹⁶. A review protocol was prospectively registered on PROSPERO

133 Systematic review

(CRD42022299275).

134 We searched PubMed and Embase databases, the Cochrane Database of Systematic Reviews, 135 PROSPERO database (www.crd.york.ac.uk/prospero), and Clinical Trials Registry 136 (www.clinicaltrials.gov) from January 2000 through December 2021 (Figure 1). We used 137 two pre-specified combinations of keywords related to diagnostic accuracy and prognostic 138 significance of stress CMR (eMethods). We also searched reference lists of all identified 139 articles for additional relevant studies, including hand-searching reviews and published meta-140 analyses. Two authors (G.B., A.D.C.) performed the screening of titles and abstracts, 141 reviewed full-text articles, and determined their eligibility. Discrepancies were resolved by 142 consensus with other reviewers (F.R., M.Y.K., A.C.). The review process was not blinded to 143 study results. Studies were eligible if they met the following criteria: (i) published as full-144 length article; (ii) English language; (iii) prospective or retrospective study design; (iv) 145 enrolling ≥ 100 patients aged ≥ 18 years; (v) reporting estimates of diagnostic accuracy of 146 stress CMR compared with invasive coronary angiography (ICA) or fractional flow reserve 147 (FFR) as reference test, and/or raw data about all-cause death, CV death, and major adverse 148 cardiovascular events (MACE, defined as composite of CV death and myocardial infarction) 149 for study participants with either positive or negative stress CMR scans. Studies were eligible 150 regardless of whether they were referred for suspected or known CAD and regardless of the

technique used for evaluation of inducible ischemia: wall motion analysis, perfusion
(qualitative, semiquantitative, fully quantitative). Two investigators (G.B., A.D.C.) abstracted
relevant data of patient populations, study-level characteristics, and outcomes from original
eligible sources. The ascertainment of clinical events was accepted as reported. The quality of
eligible studies was evaluated by QUADAS-2 tool¹⁷ and Newcastle-Ottawa Scale¹⁸ for
diagnostic and prognostic studies, respectively.

157 Statistical analysis

158 Categorical variables were reported as percentages, and continuous variables as means and 159 standard deviation or medians and interguartile range, as appropriate. We used the inverse 160 variance heterogeneity model for the meta-analysis of diagnostic studies, which proved 161 superior to the standard bivariate model¹⁹. For each study, raw data of true positives, true 162 negatives, false positives, and false negatives were either extracted from the study or 163 generated from reported diagnostic estimates. Diagnostic odds ratio (DOR), area under the 164 receiver operating characteristic (ROC) curve (AUC), sensitivity, specificity, negative (nLR) 165 and positive likelihood ratios (pLR) were calculated. A ROC plot was used to summarize 166 study-level findings. Pooled estimates of sensitivity and specificity for stress CMR derived 167 from the meta-analysis were used to generate a leaf plot illustrating the relationship between pre-test and post-test probability of CAD. In the prognostic meta-analysis, summary effect 168 169 sizes for all-cause death, CV death, and myocardial infarction have been calculated primarily 170 for presence or absence of inducible ischemia, and additionally for late gadolinium 171 enhancement (LGE). A random-effects model was used, and study-specific odds ratios (ORs) 172 were pooled using the Mantel-Haenszel method for each study outcome. The Hartung-Knapp 173 adjustment²⁰ was applied to all analyses except for those with ≤ 3 studies per group. Average effects were not calculated for outcomes reported by less than 3 studies. Inter-study 174

175 heterogeneity was assessed by I² statistic and represented as Baujat plot²¹. Significant 176 heterogeneity was considered for $I^2 \ge 50\%$. The z-statistic was computed for each endpoint of 177 interest, and the results were considered statistically significant at a p<0.05. Meta-analysis 178 results were presented by classic forest plots with point estimates of the effect size and 179 95%CIs, with square area indicating study weight. A Jackknife sensitivity analysis was 180 performed for each outcome to evaluate the robustness of the results and the impact of every 181 single study on the summary estimate of effect. The likelihood of publication bias was 182 assessed using funnel plots by displaying individual study OR with 95%CIs for the endpoints 183 of interest, with the addition of the non-parametric 'trim-and-fill' procedure to adjust for 184 funnel plot asymmetry by generating hypothetical missing studies; for all models including 185 more than 10 studies, funnel plot asymmetry was also evaluated by tests proposed by Deeks²² 186 and Egger²³ for diagnostic and prognostic studies, respectively (p<0.10 indicative of 187 significant publication bias). Subgroup analyses were performed to investigate possible 188 sources of heterogeneity and to assess the effect of selected variables, including sample size, 189 sex, CAD prevalence, thresholds of diameter stenosis, year of publication, magnetic field 190 strength, and stressor agent. Annualized event rates (AERs) for studies were calculated by 191 dividing the number of events by the follow-up duration. The low-risk period was defined as 192 the mean time interval the patient group with a negative test remained below the threshold of 1% cumulative MACE rate²⁴. All statistical analyses were performed using R version 4.1.0. 193 194 (R packages and functions are detailed in eMethods).

195 Results

- 196 Of 3,144 citations identified and retrieved for title and abstract evaluation, we reviewed full-
- text of 237 potentially relevant articles and finally included 33 diagnostic studies and 31
- 198 prognostic studies, published between 2002 and 2021 (Figure 1). Study-level prevalence of
- 199 CAD ranged between 11% and 83% in diagnostic studies. Mean follow-up was 3.5 years
- 200 (range 0.9 to 8.8) for a total of 381,357 person-years. The overall quality of included studies
- 201 was high (eFigure 1, eTable 3). Main characteristics of studies included in the diagnostic
- and prognostic meta-analyses are summarized in eTable 1 and eTable 2.
- 203

204 Diagnostic Meta-Analysis

- 205 Stress CMR vs ICA
- 206 Diagnostic accuracy of stress CMR compared with ICA as the reference test was reported in
- 207 30 studies^{8,10,25-52}, pooling 7,496 symptomatic patients with known (n=537) or suspected
- 208 CAD (n=2825).
- 209 On a per-patient analysis, stress CMR yielded a pooled DOR of 19.1 (95%CI:12.6-29.1), a
- 210 sensitivity of 84% (95%CI:79-88%), a specificity of 79% (95%CI:73-84%), a pLR of 4.0
- 211 (95%CI:3.0-5.3), a nLR of 0.21 (95%CI:0.2-0.3), and AUC of 0.81 (95%CI:0.78-0.84) for
- 212 the detection of anatomically obstructive CAD (Figure 2).
- 213 On a per-vessel analysis, stress CMR yielded pooled DOR of 21.0 (95%CI:10.2-43.4),
- 214 sensitivity of 72% (95%CI:61-81%), specificity of 89% (95%CI:82-94%), pLR of 6.7
- 215 (95%CI:3.8-11.8), nLR of 0.3 (95%CI:0.2-0.5), and AUC of 0.82 (95%CI:0.76-0.87).

- 217 Stress CMR vs invasive FFR
- 218 Diagnostic accuracy of stress CMR compared with invasive FFR as the reference test was
- reported in 8 studies $^{10,27,37,44,45,53-55}$, pooling 1,196 symptomatic patients with known (n=354)

- or suspected (n=593) CAD. On per-patient analysis, stress CMR yielded pooled DOR of 26.4
- 221 (95%CI:10.6-65.9), sensitivity of 81% (95%CI:68-89), specificity of 86% (95%CI:75-93%),
- 222 a pLR of 5.8 (95%CI:3.0-11.4), nLR of 0.2 (95%CI:0.1-0.4), and AUC of 0.84 (0.77-0.89)
- for detection of functionally obstructive CAD (Figure 2). On per-vessel analysis, stress CMR
- 224 yielded pooled DOR of 24.1 (95%CI:5.5-105.4), sensitivity of 70% (95%CI:46-86%),
- 225 specificity of 91% (95%CI:74-97%), pLR of 8.0 (95%CI:2.4-26.5), nLR of 0.3 (95%CI:0.1-
- **226** 0.8), and AUC of 0.83 (95%CI:0.70-0.91).
- 227
- 228 Prognostic Meta-Analysis

229 All-cause mortality

- A total of 11 studies⁵⁶⁻⁶⁶ pooling 51,166 individuals reported all-cause mortality. Presence of
 inducible ischemia was associated with two-fold increased mortality (OR 2.0; 95%CI:1.7-2.3,
 p<0.005; Figure 3A). Presence of LGE was associated with two-fold increased mortality
 (OR 2.22; 95%CI:1.99-2.47, p<0.001; Figure 4A). Pooled AERs for all-cause mortality in
 patients with and without inducible ischemia were respectively 3.0% and 1.4% (p<0.0001;
 Figure 5A). Pooled AERs for all-cause mortality in patients with and without LGE were
 respectively 4.5% and 2.3% (p<0.0001; Figure 5A).
- 237

238 Cardiovascular mortality

- A total of 14 studies^{62,64,66-77} pooling 12,252 individuals reported CV mortality data Presence
- 240 of inducible ischemia detected by stress CMR was associated with six-fold increased CV
- 241 mortality (OR 6.4 95%CI:4.5-9.1, p<0.0001; Figure 3B). Presence of LGE was associated
- 242 with six-fold increased CV mortality (OR 6.03; 95%CI:2.76-13.13, p<0.001; Figure 4B).
- 243 Pooled AERs for CV death in patients with and without inducible ischemia were respectively
- 244 2.5% and 0.6% (p<0.0001; Figure 5A). Pooled AERs for CV mortality in patients with and

without LGE were respectively 2.51% and 0.71% (p<0.0001; Figure 5A).

246

247 *MACE*

- A total of 22 studies^{7,25,59,60,64,66-69,72-84} pooling 17,084 individuals reported MACE data.
- 249 Presence of inducible ischemia was associated with five-fold increased risk of incident
- 250 MACE (OR 5.3 95%CI:4.0-7.0, p<0.000; Figure 3C). Presence of LGE was associated with
- 251 five-fold increased risk of MACE (OR 5.42; 95%CI:3.42-8.6, p<0.001; Figure 4C). Pooled
- AERs for MACE in patients with and without ischemia were respectively 4.3% and 1.0%
- 253 (p<0.0001; Figure 5A). Pooled AERs for MACE in patients with and without LGE were
- respectively 2.9% and 0.78%, p<0.0001; Figure 5A). Combining ischemia and LGE
- 255 information, we documented the highest AER when both present and the lowest AER when
- both absent (Figure 5B). At mean follow-up of 3.5 years, normal stress CMR, featuring
- absence of inducible ischemia and no LGE, was associated with a pooled AER of 0.58%,
- whilst the presence of ischemia and LGE yielded a pooled AER of 4.24%.

259

- 260 Assessment of study quality and publication bias
- 261 According to QUADAS-2 tool, risk of bias was low in 29 of 33 diagnostic studies (eFigure

262 3). Of 31 prognostic studies, 15 studies scored 9 stars, and 16 studies scored 8 stars according

- to the Newcastle-Ottawa Scale (eTable 3). In ICA studies, Deeks' test ruled-out small-study
- bias and publication bias (p=0.34) (eFigure 2). Deeks' test was not performed in FFR studies
- since the number of studies was insufficient. With regards to prognostic studies, we ruled-out
- 266 publication bias by visual inspection of funnel plots and Egger's test of intercept that was
- 267 non-significant for each outcome (eFigure 3).

268 Subgroup analysis

- 269 Results are summarized in eTables 4, 5. Stress CMR demonstrated higher diagnostic
- 270 performance for detection of anatomically and functionally obstructive CAD in two
- 271 scenarios: suspected CAD and 3-Tesla. In FFR studies, higher diagnostic accuracy was
- observed in women or when lowering FFR cut point to 0.75. In ICA studies, quantitative
- assessment yielded higher DOR and specificity compared with visual assessment, and
- 274 dipyridamole achieved overall higher accuracy compared with adenosine.

275

276 Sensitivity analysis

- 277 Two diagnostic studies^{10,85} were visually and quantitatively identified as outliers in the ICA
- analysis (eFigure 2). Removal of the two outliers increased diagnostic accuracy with a
- pooled DOR of 25.2 (eFigure 4). In the FFR analysis, removal of the single outlier¹⁰
- improved diagnostic summary estimates, attaining a pooled DOR of 41.3 (eFigure 5). No
- single prognostic study affected the pooled OR for each endpoint of interest.

282 Discussion

283 The current analysis covers the last 20 years of clinical research in the field of stress 284 CMR imaging using state-of-the-art statistical methods for quantitative data synthesis. We 285 provide the largest summary evidence available by pooling more than 65,000 patients and 286 381,357 person-years of follow-up and reaffirming that stress CMR imaging yields high 287 diagnostic accuracy, robust cardiac prognostication, and effective risk stratification in 288 patients with stable chest pain and known or suspected CAD. Our analysis was focused on 289 symptomatic patients, in line with current international guidelines indications on deferring or 290 eliminating unnecessary testing when the diagnostic yield is low or in asymptomatic individuals^{1,86}. 291

292 Stress CMR delivers high diagnostic accuracy consistently across multiple clinical 293 scenarios and time trend analysis. This is even more evident for detecting functionally 294 obstructive lesions assessed by FFR, which has been shown to provide optimum balance 295 between myocardial revascularization and medical treatment in the FAME trials^{87,88}. In addition to previous meta-analyses^{89,90}, our findings build on supporting better diagnostic 296 297 performance of stress CMR in the setting of suspected CAD, or when using 3-Tesla imaging, due to improved contrast resolution⁹¹⁻⁹³, and quantitative perfusion assessment, which can be 298 299 advantageous to better identify disease extent or peri-infarct ischemia than visual assessment alone in multivessel CAD, detect microvascular disease and verify stress adequacy⁹⁴. The 300 301 signal of dipyridamole outperforming adenosine studies is intriguing and possibly reflecting the incremental diagnostic value of combined perfusion and wall motion assessment⁷⁶. This 302 303 requires careful interpretation and prospective verification in regadenoson studies and needs 304 to be weighed against the cost, potential tolerability, and effectiveness of the stressor 305 agents⁹⁵.

306

In our diagnostic meta-analysis, two studies were identified as outliers that

307 showed a lower-than-average diagnostic yield of stress CMR. The Dan-NICAD randomized clinical trial¹⁰ enrolled patients with low-to-intermediate pre-test probability of CAD and an 308 309 abnormal CCTA scan prior to CMR testing and found low sensitivity for second-line 310 perfusion investigations. However, the specific study design could have led to selection bias and potentially impacted diagnostic estimates⁹⁶. The MR-IMPACT II study⁸⁵ compared stress 311 312 CMR and SPECT in a population with intermediate CAD prevalence (49%), but also a fairly 313 high number of patients with prior MI (27%), in whom it can be more difficult to 314 discriminate myocardial scarring and residual ischemia, and with expected higher prevalence 315 of microvascular disease inflating the number of false positive findings. This multicenter 316 study enrolling from 33 different institutions aimed to frame a realistic clinical environment 317 not restricted to high-volume leading centers. In both studies, measurements were performed 318 by an independent core laboratory with readers fully blinded to additional patient information 319 and results, limiting the bias of the clinical context when reporting stress CMR studies. 320 When interpreting these findings, we should remember that myocardial ischemia 321 exists as a continuum and binary categorizations have inherent limitations. Furthermore, 322 shortcomings in the accuracy of established invasive gold standards must be carefully 323 considered. Notably, FFR was firstly calibrated against non-invasive tests⁹⁷, including 324 bicycle exercise testing, thallium scintigraphy, stress echocardiography with dobutamine, 325 which were, themselves, validated against ICA as the reference test, falling into a challenging 326 circular thinking^{98,99}. An FFR threshold of ≤ 0.80 has been adopted into clinical practice 327 guidelines as an actionable value to guide revascularization, despite robust evidence supporting larger treatment benefit at lower FFR values^{100,101} and our findings indicating 328 329 better agreement with an FFR threshold of 0.75. 330 More recently, the MR-INFORM trial randomized 918 symptomatic patients at high

331 pre-test probability of CAD to undergo ICA plus FFR versus stress CMR-guided

332 care⁹. MACE rate and percentage of patients free from angina were similar for both strategies 333 at 1-year, yet the use of stress CMR was associated with a noticeably lower incidence of 334 downstream ICA and coronary revascularization than was the use of FFR. Similar findings 335 have been reported in the setting of low-risk acute coronary syndromes by a network meta-336 analysis of diagnostic randomized controlled trials demonstrating how stress CMR was 337 associated with fewer referrals to downstream ICA than coronary CT angiography or other 338 non-invasive imaging modalities, and without obvious impact on subsequent risk of 339 myocardial infarction¹⁰².

340 This evidence translates into the uniquely favorable cost-effective profile of stress CMR imaging compared to its relevant comparators¹⁰³. According to a cost-effectiveness 341 342 analysis comparing different first-line diagnostic pathways for stable chest pain and a 343 decision-analytic model to estimate lifetime health care costs and quality-adjusted life-years 344 derived from the multicenter SPINS study, stress CMR strongly dominated SPECT and 345 coronary CT angiography strategies either when considering all MACE or hard events 346 alone¹⁰⁴. Thus, having access to CMR is a win situation for patients and can lead to 347 significant cost savings by reducing the need for additional, unnecessary tests and revascularization procedures^{105,106}. 348

349 The prognostic value of non-invasive cardiac investigations has been the objective of a 350 previous meta-analysis raising the possibility of clinical equipoise for prediction of CV death 351 and myocardial infarction ¹³. While the message that any negative test conveys excellent 352 prognosis is reassuring and challenges need for further downstream testing, post-test 353 probability of disease needs adjustment for baseline population event risk and should always 354 be carefully interpreted in the context of pre-test probability, prevalence of disease and 355 according to the clinical scenario. In our analysis, the presence of inducible ischemia by 356 stress CMR was a robust predictor of increased mortality and risk of MACE, further

heightened by the presence of LGE. Conversely, normal stress CMR was associated with
very low incidence of adverse cardiovascular events, yielding a low-risk post-test period of at
least 3.5 years. Our data echoes the results of previous meta-analyses^{107,108} and of the EuroCMR registry⁵, where patients with suspected CAD and a negative stress CMR experienced
an AER for hard cardiovascular endpoints of less than 1%.

Ultimately, the prognostic value of stress CMR, either performed with vasodilators or
dobutamine, is incremental to traditional risk factors^{66,81}. Further studies are needed to
establish the optimal CMR method for absolute quantification of myocardial blood flow and
the optimal ischemic threshold associated with larger treatment effect, as a tipping point
useful to identify patients who would most benefit from myocardial revascularization versus
safe deferral.

368 Strengths and limitations

369

370 We summarized the largest evidence available making use of the best methods for 371 quantitative synthesis and provided robust estimates on the diagnostic and prognostic value 372 of stress CMR. We provide new information on the duration of low-risk period for MACE 373 following a normal stress CMR. This knowledge has the potential to inform future clinical 374 guidelines about ideal time intervals for repeat imaging and to provide useful guidance to 375 subsequent management of symptomatic patients with initial normal imaging results or 376 subclinical disease¹⁰⁹. Results of subgroup analyses also suggest better diagnostic 377 performance of stress CMR in the setting of suspected CAD, especially when using 3-Tesla 378 imaging and fully quantitative approaches. We acknowledge a few limitations. Firstly, we 379 did not compare the yield of stress CMR to other imaging modalities as it was beyond the scope of the current work, and literature specifically addressing these topics already exist ¹¹⁰⁻ 380 381 ¹¹². Secondly, our results are mostly derived from observational studies reflecting different

382	guideline recommendations across two decades of practice. Within this timespan, thresholds
383	for coronary stenosis have changed ¹¹³ , methods for estimation of pre-test probabilities of
384	obstructive CAD have been updated and recalibrated ^{1,86} , and CMR protocols have been
385	implemented with quantitative perfusion assessment ⁶¹ , new tools for evaluation of stress
386	adequacy ¹¹⁴⁻¹¹⁶ , more widespread use of regadenoson ¹¹⁷ , and other disruptive technical
387	innovations ¹¹⁸⁻¹²⁰ . Finally, we recognize lack of information about medical therapy,
388	completeness of myocardial revascularization, extent of inducible ischemia, degree of
389	myocardial fibrosis, and prevalence of microvascular dysfunction. Despite intrinsic
390	challenges and limitations of study-level meta-analysis, including limited adjustment for
391	confounding factors and ecological fallacy, we attempted to synthesize the results in a robust
392	manner addressing potential bias.

393

394 Conclusions

In patients with stable chest pain and known or suspected CAD, stress CMR yields high
diagnostic accuracy to detect both anatomically and functionally significant CAD, with 3Tesla and quantitative perfusion approaches delivering higher diagnostic performance. Stress
CMR provides also robust prognostic information and effective risk stratification. While
presence of ischemia and LGE portend higher CV risk and mortality, normal stress CMR is
associated with very low risk of MACE for at least 3.5 years.

401 **Contributors**

- 402 FR, GB, MYK, CBD had full access to all the data in the study and take responsibility of the
- 403 data and accuracy of the data analysis. FR, AC, LC, ADC, AF contributed to the study concept
- 404 and design. FR, GBD, LC, AC, ADC contributed to the acquisition of data. All authors
- 405 analyzed and interpreted the data. SG was the study supervisor. GBD and FR did the statistical
- 406 analysis. FR drafted the manuscript with critical revision for important intellectual content
- 407 from all co-authors. FR, GB, MYK, AF, SEP and CBD contributed to the revision process with
- 408 critical revision for important intellectual content from all co-authors.
- **409 Funding/Support:** no funding.
- 410 Data sharing statement: Authors agree to make data and materials supporting the results or
- 411 analyses presented available upon reasonable request.
- 412 **Disclosures:** AF: consultant and lecture fees from Medtronic Inc, Argenx BV and Finapres
- 413 Medical Systems; FR: lecture fees from PIAM pharmaceuticals and Takeda Pharmaceutical;
- 414 SEP: consultancy to Cardiovascular Imaging Inc, Calgary, Alberta, Canada; CBD: lecture
- 415 fees from Circle Cardiovascular Imaging, Bayer and Siemens Healthineers.
- 416 The remaining authors have nothing to disclose.
- 417
- 418 Supplemental Materials
- eMethods
- **420** eFigures 1-5
- 421 eTables 1-5

422 References

423 1. Knuuti J, Wijns W, Saraste A, et al. 2019 ESC Guidelines for the diagnosis and
424 management of chronic coronary syndromes. *Eur Heart J*. Jan 14 2020;41(3):407-477.
425 doi:10.1093/eurheartj/ehz425

426 2. Patel AR, Salerno M, Kwong RY, Singh A, Heydari B, Kramer CM. Stress Cardiac
427 Magnetic Resonance Myocardial Perfusion Imaging: JACC Review Topic of the Week. *J Am*428 *Coll Cardiol.* Oct 19 2021;78(16):1655-1668. doi:10.1016/j.jacc.2021.08.022

3. Edvardsen T, Asch FM, Davidson B, et al. Non-invasive imaging in coronary
syndromes: recommendations of the European Association of Cardiovascular Imaging and the
American Society of Echocardiography, in collaboration with the American Society of Nuclear
Cardiology, Society of Cardiovascular Computed Tomography, and Society for Cardiovascular
Magnetic Resonance. *Eur Heart J Cardiovasc Imaging*. Jan 24 2022;23(2):e6-e33.
doi:10.1093/ehjci/jeab244

435 4. Gulati M, Levy PD, Mukherjee D, al. 2021 et 436 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of 437 Chest Pain: A Report of the American College of Cardiology/American Heart Association Joint 438 Committee on Clinical Practice Guidelines. Circulation. Nov 30 2021;144(22):e368-e454. 439 doi:10.1161/CIR.000000000001029

5. Bruder O, Wagner A, Lombardi M, et al. European cardiovascular magnetic resonance
(EuroCMR) registry – multi national results from 57 centers in 15 countries. *Journal of Cardiovascular Magnetic Resonance*. 2013/01/18 2013;15(1):9. doi:10.1186/1532-429X-15-9

6. Kwong RY, Petersen SE, Schulz-Menger J, et al. The global cardiovascular magnetic
resonance registry (GCMR) of the society for cardiovascular magnetic resonance (SCMR): its
goals, rationale, data infrastructure, and current developments. *J Cardiovasc Magn Reson*. Jan
20 2017;19(1):23. doi:10.1186/s12968-016-0321-7

Kwong RY, Ge Y, Steel K, et al. Cardiac Magnetic Resonance Stress Perfusion
Imaging for Evaluation of Patients With Chest Pain. J Am Coll Cardiol. Oct 8
2019;74(14):1741-1755. doi:10.1016/j.jacc.2019.07.074

- 450 8. Arai AE, Schulz-Menger J, Berman D, et al. Gadobutrol-Enhanced Cardiac Magnetic
 451 Resonance Imaging for Detection of Coronary Artery Disease. *J Am Coll Cardiol*. Sep 29
 452 2020;76(13):1536-1547. doi:10.1016/j.jacc.2020.07.060
- 453 9. Nagel E, Greenwood JP, McCann GP, et al. Magnetic Resonance Perfusion or
 454 Fractional Flow Reserve in Coronary Disease. *N Engl J Med.* Jun 20 2019;380(25):2418-2428.
 455 doi:10.1056/NEJMoa1716734
- 10. Nissen L, Winther S, Westra J, et al. Diagnosing coronary artery disease after a positive
 coronary computed tomography angiography: the Dan-NICAD open label, parallel, head to
 head, randomized controlled diagnostic accuracy trial of cardiovascular magnetic resonance
 and myocardial perfusion scintigraphy. *Eur Heart J Cardiovasc Imaging*. Apr 1
 2018;19(4):369-377. doi:10.1093/ehjci/jex342
- Haberkorn SM, Haberkorn SI, Bonner F, Kelm M, Hopkin G, Petersen SE. Vasodilator
 Myocardial Perfusion Cardiac Magnetic Resonance Imaging Is Superior to Dobutamine Stress
 Echocardiography in the Detection of Relevant Coronary Artery Stenosis: A Systematic
 Review and Meta-Analysis on Their Diagnostic Accuracy. *Front Cardiovasc Med.*2021;8:630846. doi:10.3389/fcvm.2021.630846
- 466 12. Danad I, Szymonifka J, Twisk JWR, et al. Diagnostic performance of cardiac imaging
 467 methods to diagnose ischaemia-causing coronary artery disease when directly compared with
 468 fractional flow reserve as a reference standard: a meta-analysis. *Eur Heart J*. Apr 1
 469 2017;38(13):991-998. doi:10.1093/eurheartj/ehw095
- 470 13. Smulders MW, Jaarsma C, Nelemans PJ, et al. Comparison of the prognostic value of

471 negative non-invasive cardiac investigations in patients with suspected or known coronary
472 artery disease-a meta-analysis. *Eur Heart J Cardiovasc Imaging*. Sep 1 2017;18(9):980-987.
473 doi:10.1093/ehjci/jex014

474 14. El Aidi H, Adams A, Moons KG, et al. Cardiac magnetic resonance imaging findings
475 and the risk of cardiovascular events in patients with recent myocardial infarction or suspected
476 or known coronary artery disease: a systematic review of prognostic studies. *J Am Coll Cardiol.*477 Mar 25 2014;63(11):1031-45. doi:10.1016/j.jacc.2013.11.048

478 15. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated
479 guideline for reporting systematic reviews. *Systematic Reviews*. 2021/03/29 2021;10(1):89.
480 doi:10.1186/s13643-021-01626-4

- 481 16. Higgins J, Thomas J, Chandler J, et al. *Cochrane Handbook for Systematic Reviews of*482 *Interventions version 6.3* 2022.
- 483 17. Whiting PF, Rutjes AW, Westwood ME, et al. QUADAS-2: a revised tool for the
 484 quality assessment of diagnostic accuracy studies. *Ann Intern Med.* Oct 18 2011;155(8):529485 36. doi:10.7326/0003-4819-155-8-201110180-00009
- 486 18. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies
 487 in meta-analyses. <u>http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp</u> (11
 488 November 2021, date last accessed).
- 489 19. Furuya-Kanamori L, Kostoulas P, Doi SAR. A new method for synthesizing test
 490 accuracy data outperformed the bivariate method. *Journal of Clinical Epidemiology*.
 491 2021/04/01/2021;132:51-58. doi:https://doi.org/10.1016/j.jclinepi.2020.12.015
- 492 20. Hartung J, Knapp G. A refined method for the meta-analysis of controlled clinical trials
 493 with binary outcome. *Statistics in medicine*. 2001;20(24):3875-3889.
- 494 21. Baujat B, Mahé C, Pignon JP, Hill C. A graphical method for exploring heterogeneity
 495 in meta-analyses: application to a meta-analysis of 65 trials. *Statistics in medicine*.
 496 2002;21(18):2641-2652.
- 497 22. Deeks JJ, Macaskill P, Irwig L. The performance of tests of publication bias and other
 498 sample size effects in systematic reviews of diagnostic test accuracy was assessed. *J Clin*499 *Epidemiol.* Sep 2005;58(9):882-93. doi:10.1016/j.jclinepi.2005.01.016
- 500 23. Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a
 501 simple, graphical test. *BMJ*. 1997;315(7109):629-634. doi:10.1136/bmj.315.7109.629
- 502 24. Hachamovitch R, Hayes S, Friedman JD, et al. Determinants of risk and its temporal
 503 variation in patients with normal stress myocardial perfusion scans: what is the warranty period
 504 of a normal scan? *J Am Coll Cardiol*. Apr 16 2003;41(8):1329-40. doi:10.1016/s0735505 1097(03)00125-6
- 506 25. Becker M, Hundemer A, Zwicker C, et al. Detection of coronary artery disease in
 507 postmenopausal women: the significance of integrated stress imaging tests in a 4-year
 508 prognostic study. *Clin Res Cardiol.* Mar 2015;104(3):258-71. doi:10.1007/s00392-014-0780509 5
- 510 26. Bernhardt P, Spiess J, Levenson B, et al. Combined assessment of myocardial perfusion
 511 and late gadolinium enhancement in patients after percutaneous coronary intervention or
 512 bypass grafts: a multicenter study of an integrated cardiovascular magnetic resonance protocol.
 513 *JACC Cardiovasc Imaging*. Nov 2009;2(11):1292-300. doi:10.1016/j.jcmg.2009.05.011
- 514 Bettencourt N, Chiribiri A, Schuster A, et al. Cardiac magnetic resonance myocardial 27. 515 perfusion imaging for detection of functionally significant obstructive coronary artery disease: 516 prospective Cardiol. 30 2013;168(2):765-73. а study. Int JSep doi:10.1016/j.ijcard.2012.09.231 517
- 518 28. Biglands JD, Ibraheem M, Magee DR, Radjenovic A, Plein S, Greenwood JP.
 519 Quantitative Myocardial Perfusion Imaging Versus Visual Analysis in Diagnosing Myocardial
 520 Ischemia: A CE-MARC Substudy. *JACC Cardiovasc Imaging*. May 2018;11(5):711-718.

- **521** doi:10.1016/j.jcmg.2018.02.019
- 522 29. Chen MY, Bandettini WP, Shanbhag SM, et al. Concordance and diagnostic accuracy
 523 of vasodilator stress cardiac MRI and 320-detector row coronary CTA. *Int J Cardiovasc*524 *Imaging*. Jan 2014;30(1):109-19. doi:10.1007/s10554-013-0300-0
- 30. Doesch C, Seeger A, Hoevelborn T, et al. Adenosine stress cardiac magnetic resonance
 imaging for the assessment of ischemic heart disease. *Clin Res Cardiol*. Dec 2008;97(12):90512. doi:10.1007/s00392-008-0708-z
- 528 31. Doyle M, Fuisz A, Kortright E, et al. The impact of myocardial flow reserve on the
 529 detection of coronary artery disease by perfusion imaging methods: an NHLBI WISE study. J
 530 *Cardiovasc Magn Reson.* Jul 2003;5(3):475-85. doi:10.1081/jcmr-120022263
- 32. Gebker R, Frick M, Jahnke C, et al. Value of additional myocardial perfusion imaging
 during dobutamine stress magnetic resonance for the assessment of intermediate coronary
 artery disease. *Int J Cardiovasc Imaging*. Jan 2012;28(1):89-97. doi:10.1007/s10554-0109764-3
- 535 33. Gebker R, Jahnke C, Manka R, et al. Additional value of myocardial perfusion imaging
 536 during dobutamine stress magnetic resonance for the assessment of coronary artery disease.
 537 *Circ Cardiovasc Imaging*. Sep 2008;1(2):122-30. doi:10.1161/CIRCIMAGING.108.779108
- 538 34. Gebker R, Jahnke C, Paetsch I, et al. Diagnostic performance of myocardial perfusion
- 539 MR at 3 T in patients with coronary artery disease. *Radiology*. Apr 2008;247(1):57-63.
 540 doi:10.1148/radiol.2471070596
- 541 35. Greenwood JP, Maredia N, Younger JF, et al. Cardiovascular magnetic resonance and
 542 single-photon emission computed tomography for diagnosis of coronary heart disease (CE543 MARC): a prospective trial. *Lancet*. Feb 4 2012;379(9814):453-60. doi:10.1016/s0140544 6736(11)61335-4
- 545 36. Greulich S, Steubing H, Birkmeier S, et al. Impact of arrhythmia on diagnostic
 546 performance of adenosine stress CMR in patients with suspected or known coronary artery
 547 disease. *J Cardiovasc Magn Reson*. Nov 5 2015;17:94. doi:10.1186/s12968-015-0195-0
- 548 37. Hamada S, Gotschy A, Wissmann L, et al. Multi-centre study of whole-heart dynamic
 549 3D cardiac magnetic resonance perfusion imaging for the detection of coronary artery disease
 550 defined by fractional flow reserve: gender based analysis of diagnostic performance. *Eur Heart*551 *J Cardiovasc Imaging*. Oct 1 2017;18(10):1099-1106. doi:10.1093/ehjci/jex160
- 38. Husser O, Bodi V, Sanchis J, et al. Additional diagnostic value of systolic dysfunction
 induced by dipyridamole stress cardiac magnetic resonance used in detecting coronary artery
 disease. *Rev Esp Cardiol*. Apr 2009;62(4):383-91. doi:10.1016/s1885-5857(09)71665-2
- 39. Ishida N, Sakuma H, Motoyasu M, et al. Noninfarcted Myocardium: Correlation
 between Dynamic First-Pass Contrast-enhanced Myocardial MR Imaging and Quantitative
 Coronary Angiography. *Radiology*. 2003/10/01 2003;229(1):209-216.
 doi:10.1148/radiol.2291021118
- 559 40. Klem I, Greulich S, Heitner JF, et al. Value of cardiovascular magnetic resonance stress
 560 perfusion testing for the detection of coronary artery disease in women. *JACC Cardiovasc*561 *Imaging*. Jul 2008;1(4):436-45. doi:10.1016/j.jcmg.2008.03.010
- 562 41. Klumpp B, Miller S, Seeger A, et al. Is the diagnostic yield of myocardial stress
 563 perfusion MRI impaired by three-vessel coronary artery disease? *Acta Radiol*. Feb
 564 2015;56(2):143-51. doi:10.1177/0284185114523758
- 565 42. Kotecha T, Chacko L, Chehab O, et al. Assessment of Multivessel Coronary Artery
 566 Disease Using Cardiovascular Magnetic Resonance Pixelwise Quantitative Perfusion
 567 Mapping. JACC Cardiovasc Imaging. Dec 2020;13(12):2546-2557.
 568 doi:10.1016/j.jcmg.2020.06.041
- Manka R, Jahnke C, Kozerke S, et al. Dynamic 3-dimensional stress cardiac magnetic
 resonance perfusion imaging: detection of coronary artery disease and volumetry of myocardial

- 571 hypoenhancement before and after coronary stenting. J Am Coll Cardiol. Jan 25
 572 2011;57(4):437-44. doi:10.1016/j.jacc.2010.05.067
- 573 Manka R, Paetsch I, Kozerke S, et al. Whole-heart dynamic three-dimensional 44. 574 magnetic resonance perfusion imaging for the detection of coronary artery disease defined by fractional flow reserve: determination of volumetric myocardial ischaemic burden and 575 576 coronary lesion location. Eur Heart Aug 2012;33(16):2016-24. J. 577 doi:10.1093/eurheartj/ehs170
- 578 45. Manka R, Wissmann L, Gebker R, et al. Multicenter evaluation of dynamic three579 dimensional magnetic resonance myocardial perfusion imaging for the detection of coronary
 580 artery disease defined by fractional flow reserve. *Circ Cardiovasc Imaging*. May
 581 2015;8(5)doi:10.1161/CIRCIMAGING.114.003061
- 46. Merkle N, Wohrle J, Nusser T, et al. Diagnostic performance of magnetic resonance
 first pass perfusion imaging is equally potent in female compared to male patients with
 coronary artery disease. *Clin Res Cardiol.* Jan 2010;99(1):21-8. doi:10.1007/s00392-0090071-8
- 586 47. Min JY, Ko SM, Song IY, Yi JG, Hwang HK, Shin JK. Comparison of the Diagnostic
 587 Accuracies of 1.5T and 3T Stress Myocardial Perfusion Cardiovascular Magnetic Resonance
 588 for Detecting Significant Coronary Artery Disease. *Korean J Radiol.* Nov-Dec
 589 2018;19(6):1007-1020. doi:10.3348/kjr.2018.19.6.1007
- 48. Motwani M, Maredia N, Fairbairn TA, et al. High-resolution versus standard-resolution
 cardiovascular MR myocardial perfusion imaging for the detection of coronary artery disease. *Circ Cardiovasc Imaging*. May 1 2012;5(3):306-13.
 doi:10.1161/CIRCIMAGING.111.971796
- 49. Pilz G, Bernhardt P, Klos M, Ali E, Wild M, Höfling B. Clinical implication of
 adenosine-stress cardiac magnetic resonance imaging as potential gatekeeper prior to invasive
 examination in patients with AHA/ACC class II indication for coronary angiography. *Clin Res Cardiol.* Oct 2006;95(10):531-8. doi:10.1007/s00392-006-0422-7
- 50. Schwitter J, Wacker CM, van Rossum AC, et al. MR-IMPACT: comparison of
 perfusion-cardiac magnetic resonance with single-photon emission computed tomography for
 the detection of coronary artery disease in a multicentre, multivendor, randomized trial. *Eur Heart J.* Feb 2008;29(4):480-9. doi:10.1093/eurheartj/ehm617
- 51. Schwitter J, Wacker CM, Wilke N, et al. MR-IMPACT II: Magnetic Resonance
 Imaging for Myocardial Perfusion Assessment in Coronary artery disease Trial: perfusioncardiac magnetic resonance vs. single-photon emission computed tomography for the detection
 of coronary artery disease: a comparative multicentre, multivendor trial. *Eur Heart J*. Mar
 2013;34(10):775-81. doi:10.1093/eurheartj/ehs022
- 52. Takase B, Nagata M, Kihara T, et al. Whole-heart dipyridamole stress first-pass
 myocardial perfusion MRI for the detection of coronary artery disease. *Jpn Heart J*. May
 2004;45(3):475-86. doi:10.1536/jhj.45.475
- 53. Ebersberger U, Makowski MR, Schoepf UJ, et al. Magnetic resonance myocardial
 perfusion imaging at 3.0 Tesla for the identification of myocardial ischaemia: comparison with
 coronary catheter angiography and fractional flow reserve measurements. *Eur Heart J Cardiovasc Imaging*. Dec 2013;14(12):1174-80. doi:10.1093/ehjci/jet074
- 614 54. Ramos V, Bettencourt N, Silva J, et al. Noninvasive anatomical and functional
 615 assessment of coronary artery disease. *Rev Port Cardiol.* Apr 2015;34(4):223-32.
 616 doi:10.1016/j.repc.2014.10.008
- 617 55. Watkins S, McGeoch R, Lyne J, et al. Validation of magnetic resonance myocardial
 618 perfusion imaging with fractional flow reserve for the detection of significant coronary heart
 619 disease. *Circulation*. Dec 1 2009;120(22):2207-13.
 620 doi:10.1161/CIRCULATIONAHA.109.872358

621 56. Catalano O, Moro G, Mori A, et al. Cardiac Magnetic Resonance in Stable Coronary
622 Artery Disease: Added Prognostic Value to Conventional Risk Profiling. *Biomed Res Int.*623 2018;2018:2806148. doi:10.1155/2018/2806148

57. Esteban-Fernández A, Bastarrika G, Castanon E, et al. Prognostic role of stress cardiac
magnetic resonance in the elderly. *Rev Esp Cardiol (Engl Ed)*. Mar 2020;73(3):241-247.
doi:10.1016/j.rec.2019.02.007

58. Heitner JF, Kim RJ, Kim HW, et al. Prognostic Value of Vasodilator Stress Cardiac
Magnetic Resonance Imaging: A Multicenter Study With 48 000 Patient-Years of Follow-up. *JAMA Cardiol.* Mar 1 2019;4(3):256-264. doi:10.1001/jamacardio.2019.0035

- 630 59. Hundley WG, Morgan TM, Neagle CM, Hamilton CA, Rerkpattanapipat P, Link KM.
 631 Magnetic resonance imaging determination of cardiac prognosis. *Circulation*. Oct 29
 632 2002;106(18):2328-33. doi:10.1161/01.cir.0000036017.46437.02
- 633 60. Klumpp B, Seeger A, Bretschneider C, et al. Is myocardial stress perfusion MR634 imaging suitable to predict the long term clinical outcome after revascularization? *Eur J Radiol*.
 635 Oct 2013;82(10):1776-82. doi:10.1016/j.ejrad.2013.06.003
- 636 61. Knott KD, Seraphim A, Augusto JB, et al. The Prognostic Significance of Quantitative
 637 Myocardial Perfusion: An Artificial Intelligence-Based Approach Using Perfusion Mapping.
 638 *Circulation*. Apr 21 2020;141(16):1282-1291. doi:10.1161/circulationaha.119.044666
- 639 62. Macwar RR, Williams BA, Shirani J. Prognostic value of adenosine cardiac magnetic
 640 resonance imaging in patients presenting with chest pain. *Am J Cardiol.* Jul 1 2013;112(1):46641 50. doi:10.1016/j.amjcard.2013.02.054
- 642 63. Marcos-Garces V, Gavara J, Monmeneu JV, et al. Vasodilator Stress CMR and All643 Cause Mortality in Stable Ischemic Heart Disease: A Large Retrospective Registry. *JACC*644 *Cardiovasc Imaging*. Aug 2020;13(8):1674-1686. doi:10.1016/j.jcmg.2020.02.027
- 645 64. Nagel E, Greenwood JP, McCann GP, et al. Magnetic Resonance Perfusion or
 646 Fractional Flow Reserve in Coronary Disease. *N Engl J Med.* Jun 20 2019;380(25):2418-2428.
 647 doi:10.1056/NEJMoa1716734
- 648 65. Pezel T, Unterseeh T, Garot P, et al. Long-Term Prognostic Value of Stress
 649 Cardiovascular Magnetic Resonance-Related Coronary Revascularization to Predict Death: A
 650 Large Registry With >200 000 Patient-Years of Follow-Up. *Circ Cardiovasc Imaging*. Oct
 651 2021;14(10):e012789. doi:10.1161/circimaging.121.012789
- 652 66. Shah R, Heydari B, Coelho-Filho O, et al. Stress cardiac magnetic resonance imaging
 653 provides effective cardiac risk reclassification in patients with known or suspected stable
 654 coronary artery disease. *Circulation*. Aug 6 2013;128(6):605-14.
 655 doi:10.1161/circulationaha.113.001430
- 656 67. Bingham SE, Hachamovitch R. Incremental prognostic significance of combined
 657 cardiac magnetic resonance imaging, adenosine stress perfusion, delayed enhancement, and
 658 left ventricular function over preimaging information for the prediction of adverse events.
 659 *Circulation*. Apr 12 2011;123(14):1509-18. doi:10.1161/CIRCULATIONAHA.109.907659
- 660 68. Bodi V, Husser O, Sanchis J, et al. Prognostic implications of dipyridamole cardiac MR
 661 imaging: a prospective multicenter registry. *Radiology*. Jan 2012;262(1):91-100.
 662 doi:10.1148/radiol.11110134
- 663 69. Coelho-Filho OR, Seabra LF, Mongeon FP, et al. Stress myocardial perfusion imaging
 664 by CMR provides strong prognostic value to cardiac events regardless of patient's sex. *JACC*665 *Cardiovasc Imaging*. Aug 2011;4(8):850-61. doi:10.1016/j.jcmg.2011.04.015
- Freed BH, Narang A, Bhave NM, et al. Prognostic value of normal regadenoson stress
 perfusion cardiovascular magnetic resonance. *J Cardiovasc Magn Reson*. Dec 21
 2013;15(1):108. doi:10.1186/1532-429x-15-108
- Kuijpers D, van Dijkman PR, Janssen CH, Vliegenthart R, Zijlstra F, Oudkerk M.
 Dobutamine stress MRI. Part II. Risk stratification with dobutamine cardiovascular magnetic

- resonance in patients suspected of myocardial ischemia. *Eur Radiol.* Nov 2004;14(11):2046672 52. doi:10.1007/s00330-004-2426-x
- 673 72. Lo KY, Leung KF, Chu CM, Loke KL, Chan CK, Yue CS. Prognostic value of
 674 adenosine stress myocardial perfusion by cardiac magnetic resonance imaging in patients with
 675 known or suspected coronary artery disease. *Qjm.* May 2011;104(5):425-32.
 676 doi:10.1093/qjmed/hcq238
- Ng MY, Chin CY, Yap PM, et al. Prognostic value of perfusion cardiovascular
 magnetic resonance with adenosine triphosphate stress in stable coronary artery disease. J *Cardiovasc Magn Reson*. Jun 24 2021;23(1):75. doi:10.1186/s12968-021-00770-z
- 680 74. Pezel T, Garot P, Kinnel M, et al. Long-term prognostic value of ischaemia and
 681 cardiovascular magnetic resonance-related revascularization for stable coronary disease,
 682 irrespective of patient's sex: a large retrospective study. *Eur Heart J Cardiovasc Imaging*. Oct
 683 19 2021;22(11):1321-1331. doi:10.1093/ehjci/jeab186
- 684 75. Pezel T, Unterseeh T, Kinnel M, et al. Long-term prognostic value of stress perfusion
 685 cardiovascular magnetic resonance in patients without known coronary artery disease. J
 686 *Cardiovasc Magn Reson.* Apr 8 2021;23(1):43. doi:10.1186/s12968-021-00737-0
- 687 76. Pontone G, Andreini D, Bertella E, et al. Prognostic value of dipyridamole stress
 688 cardiac magnetic resonance in patients with known or suspected coronary artery disease: a mid689 term follow-up study. *Eur Radiol.* Jul 2016;26(7):2155-65. doi:10.1007/s00330-015-4064-x
- 690 77. Wallace EL, Morgan TM, Walsh TF, et al. Dobutamine cardiac magnetic resonance
 691 results predict cardiac prognosis in women with known or suspected ischemic heart disease.
 692 JACC Cardiovasc Imaging. Mar 2009;2(3):299-307. doi:10.1016/j.jcmg.2008.10.015
- 693 78. Abbasi SA, Heydari B, Shah RV, et al. Risk stratification by regadenoson stress
 694 magnetic resonance imaging in patients with known or suspected coronary artery disease. Am
 695 J Cardiol. Oct 15 2014;114(8):1198-203. doi:10.1016/j.amjcard.2014.07.041
- 696 79. Bikiri E, Mereles D, Voss A, et al. Dobutamine stress cardiac magnetic resonance
 697 versus echocardiography for the assessment of outcome in patients with suspected or known
 698 coronary artery disease. Are the two imaging modalities comparable? *Int J Cardiol.* Feb 1
 699 2014;171(2):153-60. doi:10.1016/j.ijcard.2013.11.038
- 80. Heydari B, Juan YH, Liu H, et al. Stress Perfusion Cardiac Magnetic Resonance
 Imaging Effectively Risk Stratifies Diabetic Patients With Suspected Myocardial Ischemia. *Circ Cardiovasc Imaging*. Apr 2016;9(4):e004136. doi:10.1161/circimaging.115.004136
- 703 81. Jahnke C, Nagel E, Gebker R, et al. Prognostic value of cardiac magnetic resonance
 704 stress tests: adenosine stress perfusion and dobutamine stress wall motion imaging.
 705 *Circulation*. Apr 3 2007;115(13):1769-76. doi:10.1161/circulationaha.106.652016
- Kelle S, Egnell C, Vierecke J, et al. Prognostic value of negative dobutamine-stress
 cardiac magnetic resonance imaging. *Med Sci Monit*. Oct 2009;15(10):Mt131-136.
- 83. Lubbers DD, Rijlaarsdam-Hermsen D, Kuijpers D, et al. Performance of adenosine
 "stress-only" perfusion MRI in patients without a history of myocardial infarction: a clinical
 outcome study. *Int J Cardiovasc Imaging*. Jan 2012;28(1):109-15. doi:10.1007/s10554-0109775-0
- 84. Shah RV, Heydari B, Coelho-Filho O, et al. Vasodilator stress perfusion CMR imaging
 is feasible and prognostic in obese patients. *JACC Cardiovasc Imaging*. May 2014;7(5):462714 72. doi:10.1016/j.jcmg.2013.11.011
- 85. Schwitter J, Wacker CM, Wilke N, et al. MR-IMPACT II: Magnetic Resonance
 Imaging for Myocardial Perfusion Assessment in Coronary artery disease Trial: perfusioncardiac magnetic resonance vs. single-photon emission computed tomography for the detection
 of coronary artery disease: a comparative. *European Heart Journal*. 2013;34:775-781.
 doi:10.1093/eurheartj/ehs022
- 720 86. Gulati M, Levy PD, Mukherjee D, et al. 2021

AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of
 Chest Pain: A Report of the American College of Cardiology/American Heart Association Joint
 Committee on Clinical Practice Guidelines. *Circulation*. 2021;0(0):CIR.000000000001029.
 doi:doi:10.1161/CIR.00000000001029

725 87. Tonino PA, Fearon WF, De Bruyne B, et al. Angiographic versus functional severity of coronary artery stenoses in the FAME study fractional flow reserve versus angiography in 726 727 evaluation. Am multivessel JColl Cardiol. Jun 22 2010;55(25):2816-21. 728 doi:10.1016/j.jacc.2009.11.096

729 De Bruyne B, Fearon WF, Pijls NH, et al. Fractional flow reserve-guided PCI for stable 88. 730 arterv disease. NEngl JMed. Sep 25 2014;371(13):1208-17. coronary 731 doi:10.1056/NEJMoa1408758

- 732 89. Jaarsma C, Leiner T, Bekkers SC, et al. Diagnostic performance of noninvasive
 733 myocardial perfusion imaging using single-photon emission computed tomography, cardiac
 734 magnetic resonance, and positron emission tomography imaging for the detection of
 735 obstructive coronary artery disease: a meta-analysis. J Am Coll Cardiol. May 8
 736 2012;59(19):1719-28. doi:10.1016/j.jacc.2011.12.040
- 737 90. Yang K, Yu S-q, Lu M-j, Zhao S-h. Comparison of diagnostic accuracy of stress 738 myocardial perfusion imaging for detecting hemodynamically significant coronary artery disease between cardiac magnetic resonance and nuclear medical imaging: A meta-analysis. 739 740 International Journal Cardiology. 2019/10/15/ 2019;293:278-285. of 741 doi:https://doi.org/10.1016/j.ijcard.2019.06.054
- 742 91. Cheng AS, Pegg TJ, Karamitsos TD, et al. Cardiovascular magnetic resonance
 743 perfusion imaging at 3-tesla for the detection of coronary artery disease: a comparison with
 744 1.5-tesla. *J Am Coll Cardiol*. Jun 26 2007;49(25):2440-9. doi:10.1016/j.jacc.2007.03.028
- 92. Bernhardt P, Walcher T, Rottbauer W, Wohrle J. Quantification of myocardial
 perfusion reserve at 1.5 and 3.0 Tesla: a comparison to fractional flow reserve. *Int J Cardiovasc Imaging*. Dec 2012;28(8):2049-56. doi:10.1007/s10554-012-0037-1
- 748 93. Walcher T, Ikuye K, Rottbauer W, Wöhrle J, Bernhardt P. Is contrast-enhanced cardiac
 749 magnetic resonance imaging at 3 T superior to 1.5 T for detection of coronary artery disease?
 750 *Int J Cardiovasc Imaging*. Feb 2013;29(2):355-61. doi:10.1007/s10554-012-0099-0
- 94. Sharrack N, Chiribiri A, Schwitter J, Plein S. How to do quantitative myocardial
 perfusion cardiovascular magnetic resonance. *Eur Heart J Cardiovasc Imaging*. Feb 22
 2022;23(3):315-318. doi:10.1093/ehjci/jeab193
- Vasu S, Bandettini WP, Hsu LY, et al. Regadenoson and adenosine are equivalent
 vasodilators and are superior than dipyridamole- a study of first pass quantitative perfusion
 cardiovascular magnetic resonance. *J Cardiovasc Magn Reson*. Sep 24 2013;15(1):85.
 doi:10.1186/1532-429X-15-85
- 758 96. Lijmer JG, Mol BW, Heisterkamp S, et al. Empirical Evidence of Design-Related Bias
 759 in Studies of Diagnostic Tests. JAMA. 1999;282(11):1061-1066.
 760 doi:10.1001/jama.282.11.1061
- 761 97. Pijls NH, De Bruyne B, Peels K, et al. Measurement of fractional flow reserve to assess
 762 the functional severity of coronary-artery stenoses. *N Engl J Med.* Jun 27 1996;334(26):1703763 8. doi:10.1056/NEJM199606273342604
- 98. van de Hoef TP, Meuwissen M, Escaned J, et al. Fractional flow reserve as a surrogate
 for inducible myocardial ischaemia. *Nature Reviews Cardiology*. 2013/08/01 2013;10(8):439452. doi:10.1038/nrcardio.2013.86
- 767 99. Soares A, Brown DL. The fallacies of fractional flow reserve. *International Journal of Cardiology*. 2020/03/01/ 2020;302:34-35. doi:<u>https://doi.org/10.1016/j.ijcard.2019.12.040</u>
- 769 100. Mohdnazri SR, Keeble TR, Sharp AS. Fractional Flow Reserve: Does a Cut-off Value
 770 add Value? *Interv Cardiol.* May 2016;11(1):17-26. doi:10.15420/icr.2016:7:2

101. Johnson NP, Toth GG, Lai D, et al. Prognostic value of fractional flow reserve: linking
physiologic severity to clinical outcomes. *J Am Coll Cardiol*. Oct 21 2014;64(16):1641-54.
doi:10.1016/j.jacc.2014.07.973


102. Siontis GC, Mavridis D, Greenwood JP, et al. Outcomes of non-invasive diagnostic
modalities for the detection of coronary artery disease: network meta-analysis of diagnostic
randomised controlled trials. *Bmj*. Feb 21 2018;360:k504. doi:10.1136/bmj.k504

Pandya A, Yu YJ, Ge Y, et al. Evidence-based cardiovascular magnetic resonance costeffectiveness calculator for the detection of significant coronary artery disease. *J Cardiovasc Magn Reson.* Jan 6 2022;24(1):1. doi:10.1186/s12968-021-00833-1

- 780 104. Ge Y, Pandya A, Steel K, et al. Cost-Effectiveness Analysis of Stress Cardiovascular
 781 Magnetic Resonance Imaging for Stable Chest Pain Syndromes. *JACC Cardiovasc Imaging*.
 782 Jul 2020;13(7):1505-1517. doi:10.1016/j.jcmg.2020.02.029
- 783 105. Greenwood JP, Walker S. Stress CMR Imaging for Stable Chest Pain Syndromes:
 784 Underused and Undervalued? *JACC Cardiovasc Imaging*. Jul 2020;13(7):1518-1520.
 785 doi:10.1016/j.jcmg.2020.04.006
- 786 106. Schwitter J. The SPINS Trial: Building Evidence and a Consequence? J Am Coll
 787 Cardiol. Oct 8 2019;74(14):1756-1759. doi:10.1016/j.jacc.2019.07.075
- 788 107. Gargiulo P, Dellegrottaglie S, Bruzzese D, et al. The prognostic value of normal stress
 789 cardiac magnetic resonance in patients with known or suspected coronary artery disease: a
 790 meta-analysis. *Circ Cardiovasc Imaging*. Jul 2013;6(4):574-82.
 791 doi:10.1161/circimaging.113.000035
- 108. Lipinski MJ, McVey CM, Berger JS, Kramer CM, Salerno M. Prognostic value of stress
 cardiac magnetic resonance imaging in patients with known or suspected coronary artery
 disease: a systematic review and meta-analysis. *J Am Coll Cardiol.* Aug 27 2013;62(9):82638. doi:10.1016/j.jacc.2013.03.080
- 796 Jukema R, Maaniitty T, van Diemen P, et al. Warranty period of coronary computed 109. 797 tomography angiography and [150]H2O positron emission tomography in symptomatic 798 Cardiovasc Feb 17 patients. Eur Heart JImaging. 2023;24(3):304-311. 799 doi:10.1093/ehici/jeac258
- Xu J, Cai F, Geng C, Wang Z, Tang X. Diagnostic Performance of CMR, SPECT, and
 PET Imaging for the Identification of Coronary Artery Disease: A Meta-Analysis. *Front Cardiovasc Med.* 2021;8:621389. doi:10.3389/fcvm.2021.621389
- 803 111. Pontone G, Guaricci AI, Palmer SC, et al. Diagnostic performance of non-invasive
 804 imaging for stable coronary artery disease: A meta-analysis. *Int J Cardiol*. Feb 1 2020;300:276805 281. doi:10.1016/j.ijcard.2019.10.046
- 806 112. Knuuti J, Ballo H, Juarez-Orozco LE, et al. The performance of non-invasive tests to 807 rule-in and rule-out significant coronary artery stenosis in patients with stable angina: a meta-
- analysis focused on post-test disease probability. *European Heart Journal*. 2018;39(35):33223330. doi:10.1093/eurheartj/ehy267
- 810 113. Jeremias A, Kirtane AJ, Stone GW. A Test in Context: Fractional Flow Reserve:
 811 Accuracy, Prognostic Implications, and Limitations. J Am Coll Cardiol. Jun 6
 812 2017;69(22):2748-2758. doi:10.1016/j.jacc.2017.04.019
- 813 114. Manisty C, Ripley DP, Herrey AS, et al. Splenic Switch-off: A Tool to Assess Stress
 814 Adequacy in Adenosine Perfusion Cardiac MR Imaging. *Radiology*. Sep 2015;276(3):732-40.
 815 doi:10.1148/radiol.2015142059
- 816 115. Kotecha T, Monteagudo JM, Martinez-Naharro A, et al. Quantitative cardiovascular817 magnetic resonance myocardial perfusion mapping to assess hyperaemic response to adenosine
- 818 stress. Eur Heart J Cardiovasc Imaging. Feb 22 2021;22(3):273-281.
 819 doi:10.1093/ehjci/jeaa252
- 820 116. Burrage MK, Shanmuganathan M, Masi A, et al. Cardiovascular magnetic resonance

- stress and rest T1-mapping using regadenoson for detection of ischemic heart disease compared
 to healthy controls. *Int J Cardiol.* Jun 15 2021;333:239-245. doi:10.1016/j.ijcard.2021.03.010
- 823 117. Cerqueira MD, Nguyen P, Staehr P, Underwood SR, Iskandrian AE, Investigators A-
- 824 MT. Effects of age, gender, obesity, and diabetes on the efficacy and safety of the selective
- 825 A2A agonist regadenoson versus adenosine in myocardial perfusion imaging integrated
- ADVANCE-MPI trial results. JACC Cardiovasc Imaging. May 2008;1(3):307-16.
 doi:10.1016/j.jcmg.2008.02.003
- 828 118. Steen H, Montenbruck M, Kelle S, et al. Fast-Strain Encoded Cardiac Magnetic
 829 Resonance During Vasodilator Perfusion Stress Testing. *Front Cardiovasc Med.*830 2021;8:765961. doi:10.3389/fcvm.2021.765961
- 831 119. Zhou R, Huang W, Yang Y, et al. Simple motion correction strategy reduces
 832 respiratory-induced motion artifacts for k-t accelerated and compressed-sensing cardiovascular
 833 magnetic resonance perfusion imaging. *J Cardiovasc Magn Reson*. Feb 1 2018;20(1):6.
 834 doi:10.1186/s12968-018-0427-1
- 835 120. Foley JRJ, Richmond C, Fent GJ, et al. Rapid Cardiovascular Magnetic Resonance for
 836 Ischemic Heart Disease Investigation (RAPID-IHD). JACC Cardiovasc Imaging. Jul
- 837 2020;13(7):1632-1634. doi:10.1016/j.jcmg.2020.01.029

Figure 1 - PRISMA 2020 diagrams of search results.



Flow chart of search results for (A) diagnostic and (B) prognostic studies.




Figure 2 - Diagnostic yield of stress CMR in stable chest pain.

Plot of summary receiver operating curve characteristic of stress CMR compared with ICA (A) or FFR (B) as reference. The receiver operator characteristic curve provides a graphical display of diagnostic accuracy by plotting false positive rate (or 1-specificity) in the horizontal axis and sensitivity in the vertical axis. (C) Leaf plot illustrating the relationship between pre-test and post-test probability of CAD based on pooled estimates of sensitivity and specificity for stress CMR with ICA (red) or FFR (blue) as reference. CAD, coronary artery disease; CMR, cardiovascular magnetic resonance; FFR, fractional flow reserve; ICA, invasive coronary angiography.

Figure 3. Prognostic significance of inducible ischemia in stable chest pain.

	All-cause death												
Α													
		lschem	nia (+)	Ische	mia (-)		Odds R	atio	Odds Ratio				
	Study	Events	Total	Events	Total	Weight	MH, Random	n, 95% CI	I MH, Random, 95% CI				
	T. Pezel 2021	489	2940	2190	28822	27.9%	2.43 [2.18;	2.70]	· · · · · · · · · · · · · · · · · · ·				
	V. Marcos-Garces 2020	393	2582	324	3807	24.3%	1.93 [1.65;	2.26]	+				
	K. D. Knott 2020	14	266	28	783	4.8%	1.50 [0.78;	2.89]					
	A. Esteban-Fernández 2020	4	45	11	65	1.6%	0.48 [0.14;	1.61]					
	J. F. Heitner 2019	510	2388	855	6763	26.9%	1.88 [1.66;	2.12	•				
	E. Nagel 2019	4	221	0	224	0.3%	9.29 [0.50;	173.57]					
	O. Catalano 2018	9	82	41	383	3.7%	1.03 [0.48;	2.211	_ _				
	R. Shah 2013	28	210	40	582	7.2%	2.08 [1.25;	3.48	÷-				
	B. Klumpp 2013	2	143	1	77	0.4%	1.08 [0.10;	12.08]					
	R. R. Macwar 2013	8	240	0	264	0.3%	19.34 [1.11;	336.891					
	W. G. Hundley 2002	11	93	9	186	2.6%	2.64 [1.05;						
	Total (95% CI)		9210			100.0%	1.97 [1.69;	2.31]	•				
	Heterogeneity: Tau ² = 0.0197; 0	Chi ² = 25.	38, df =	= 10 (P <	0.01); I ²	= 61%							
									0.01 0.1 1 10 100				

Cardiovascular death

В								
0		Ischen	nia (+)	Ischer	mia (-)		Odds Ratio	Odds Ratio
	Study	Events	Total	Events	Total	Weight	MH, Random, 95% Cl	MH, Random, 95% CI
	T. Pezel 2021	57	267	93	1791	19.8%	4.96 [3.46; 7.10]	
	M. Y. Ng 2021	3	38	1	170	2.2%	14.49 [1.46; 143.37]	
	T. Pezel 2021	140	738	165	2926	22.3%	3.92 [3.08; 4.99]	
	E. Nagel 2019	2	221	0	224	1.3%	5.11 [0.24; 107.13]	
	G. Pontone 2016	4	223	1	570	2.4%	10.39 [1.16; 93.50]	
	R. Shah 2013	24	210	5	582	8.7%	14.89 [5.60; 39.58]	÷ •
	R. R. Macwar 2013	15	240	0	264	1.5%	36.36 [2.16; 611.10]	
	B. H. Freed 2013	2	43	0	106	1.3%	12.83 [0.60; 272.97]	
	V. Bodi 2012	29	712	7	1010	10.6%	6.08 [2.65; 13.97]	
	S. E. Bingham 2011	20	298	10	610	11.5%	4.32 [1.99; 9.34]	- •
	O. R. Coelho-Filho 2011	18	109	3	296	6.2%	19.32 [5.56; 67.07]	÷
	K. Y. Lo 2011	2	43	2	160	2.8%	3.85 [0.53; 28.19]	
	E. L. Wallace 2009	15	60	6	161	8.4%	8.61 [3.16; 23.48]	- <u>ia</u> -
	D. Kuijpers 2004	1	68	0	112	1.2%	5.00 [0.20; 124.49]	
	Total (95% CI)		3270			100.0%	6.40 [4.48; 9.14]	\
	Heterogeneity: Tau ² = 0.13	31: Chi ² =	= 18.17	. df = 13	(P = 0.7)	15): $ ^2 = 2$	8%	

С


MACE

	Ischen	nia (+)	Ische	mia (-)		Odds Ratio		00	dds Ra	tio	
Study	Events	Total	Events	Total	Weight	MH, Random, 95% C	I N	IH, Ra	ndom,	95%	CI
. Pezel 2021	75	267	128	1791	8.1%	5.08 [3.68; 7.00]					
/I. Y. Ng 2021	3	38	2	170	1.8%	7.20 [1.16; 44.70]					_
. Pezel 2021	245	738	227	2926	8.7%	5.91 [4.82; 7.25]				+	
R. Y. Kwong 2019	60	405	93	1944	8.0%	3.46 [2.45; 4.88]					
. Nagel 2019	9	221	2	224	2.4%	4.71 [1.01; 22.06]					
3. Heydari 2016	20	79	1	94	1.5%	31.53 [4.12; 241.16]				+	
G. Pontone 2016	30	223	23	570	6.6%	3.70 [2.10; 6.52]			1	-	
A. Becker 2015	41	184	22	240	6.6%	2.84 [1.62; 4.97]				-	
R. V. Shah 2014	10	75	4	180	3.4%	6.77 [2.05; 22.34]			- -	-	
E. Bikiri 2014	65	256	51	628	7.6%	3.85 [2.58; 5.75]				•	
S. A. Abbasi 2014	5	93	3	253	2.6%	4.73 [1.11; 20.22]			_		
 Klumpp 2013 	11	143	3	77	3.0%	2.06 [0.56; 7.60]				÷	
R. Shah 2013	38	210	7	582	5.0%	18.15 [7.96; 41.37]				-	-
/. Bodi 2012	44	712	17	1010	6.6%	3.85 [2.18; 6.79]			14	•	
0. D. Lubbers 2012	0	14	1	125	0.7%	2.86 [0.11; 73.55]					_
S. E. Bingham 2011	25	298	10	610	5.5%	5.49 [2.60; 11.60]			- I -	-	
D. R. Coelho-Filho 2011	34	109	6	296	4.6%	21.91 [8.87; 54.12]				-	-
K. Y. Lo 2011	9	43	2	160	2.3%	20.91 [4.32; 101.16]				+ -	_
6. Kelle 2009	2	34	0	89	0.8%	13.77 [0.64; 294.48]			+-		_
E. L. Wallace 2009	19	60	27	161	5.9%	2.30 [1.16; 4.55]				H.	
C. Jahnke 2007	9	45	10	428	4.3%	10.45 [3.99; 27.37]				+	
V. G. Hundley 2002	12	93	6	186	4.1%	4.44 [1.61; 12.26]			-	-	
otal (95% CI)		4340		12744	100.0%	5.33 [4.04; 7.04]				∔	

Forest plots with individual and overall odds ratio estimates for all-cause death, cardiovascular death and MACE by presence or absence of inducible ischemia (A, B, C). The solid vertical line at the centre of the graph is the 'line of no effect', that is, an odds ratio of 1.0 represented. An odds ratio >1.0 favors individuals without inducible ischemia, whereas an odds ratio <1.0 favors individuals with inducible ischemia. The interrupted vertical line indicates the pooled effect estimate. The diamond size is proportional to the overall weight in this random-effects model. Blue squares indicate weighted point estimates of the effect of each single study. CI, confidence interval; MACE, major adverse cardiovascular events; MH, Mantel-Haenszel.

0.01 0.1 1

Figure 4. Prognostic significance of LGE in stable chest pain.



MACE											
C											
LGE (+) LGE (-) Odds Ratio Odds Ratio											
Study	Events	Total	Events	Total	Weight	MH, Random, 95% CI	MH, Random, 95% CI				
R. Y. Kwong 2019	84	572	69	1777	39.0%	4.26 [3.05; 5.95]	📕				
V. Bodi 2012	15	193	10	1529	19.4%	12.80 [5.67; 28.92]					
S. E. Bingham 2011	25	341	10	567	21.5%	4.41 [2.09; 9.29]	— <u>∎</u>				
R. V. Shah 2014	9	88	5	167	12.5%	3.69 [1.20; 11.38]					
B. Klumpp 2013	12	107	2	113	7.7%	7.01 [1.53; 32.11]					
Total (95% CI)		1301		4153	100.0%	5.42 [3.42; 8.60]	•				
Heterogeneity: Tau ² =	0.1130; 0	Chi ² = 6	6.54, df =	4 (P =	0.16); I ² =	39%					
							0.1 0.5 1 2 10				

Forest plots with individual and overall odds ratio estimates for all-cause death, cardiovascular death and MACE by presence or absence of or LGE (A, B, C). The solid vertical line at the centre of the graph is the 'line of no effect', that is, an odds ratio of 1.0 represented. An odds ratio >1.0 favors individuals without LGE, whereas an odds ratio <1.0 favors individuals with LGE. The interrupted vertical line indicates the pooled effect estimate. The diamond size is proportional to the overall weight in this random-effects model. Blue squares indicate weighted point estimates of the effect of each single study. CI, confidence interval; MACE, major adverse cardiovascular events; MH, Mantel-Haenszel; LGE, late gadolinium enhancement.





Figure 5. Pooled annualized event rate by stress CMR imaging findings in stable chest pain.

В

Annualized MACE rate by inducible ischemia and LGE, combined



Grouped bar charts plotting (A) pooled annualized event rate for all-cause death, CV death and MACE by inducible ischemia or LGE with colors indicating the secondary category level for each analysis; (B) pooled annualized event rate for MACE by combination of inducible ischemia and LGE information. LGE, late gadolinium enhancement; MACE, major adverse cardiovascular events.

Ricci F. et al. Stress CMR in Stable Chest Pain